标题
Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer
作者
关键词
-
出版物
Biomedicines
Volume 10, Issue 5, Pages 1047
出版商
MDPI AG
发表日期
2022-05-01
DOI
10.3390/biomedicines10051047
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
- (2022) An-Ping Shi et al. Frontiers in Immunology
- Global Patterns and Trends in Lung Cancer Incidence: A Population-Based Study
- (2021) Yanting Zhang et al. Journal of Thoracic Oncology
- Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients
- (2021) Karla Montalbán-Hernández et al. Cancers
- The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
- (2020) Quentin Lecocq et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis
- (2019) Yanfang Wang et al. Cancer Cell International
- Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
- (2019) Ila J Datar et al. CLINICAL CANCER RESEARCH
- Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
- (2019) Alexander Haragan et al. LUNG CANCER
- A robust gene signature for the prediction of early relapse in stage I-III colon cancer
- (2018) Weixing Dai et al. Molecular Oncology
- Managing Patients With Relapsed Small-Cell Lung Cancer
- (2018) Jun Gong et al. Journal of Oncology Practice
- Soluble immune checkpoints in cancer: production, function and biological significance
- (2018) Daqian Gu et al. Journal for ImmunoTherapy of Cancer
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
- (2016) Roberto Tinoco et al. IMMUNITY
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells
- (2016) Maurizio Perdicchio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity
- (2016) Marion Pepin et al. Scientific Reports
- Lung cancer: Biology and treatment options
- (2015) Hassan Lemjabbar-Alaoui et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs
- (2014) Heinz Läubli et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients
- (2014) Seon-Kyu Kim et al. Molecular Oncology
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- A Risk Model for Lung Cancer Incidence
- (2012) C. Hoggart et al. Cancer Prevention Research
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
- (2011) Roy S Herbst et al. LANCET
- Lung cancer screening
- (2010) U Pastorino BRITISH JOURNAL OF CANCER
- Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
- (2010) J. Subramanian et al. JNCI-Journal of the National Cancer Institute
- A Clinical Model to Estimate Recurrence Risk in Resected Stage I Non-Small Cell Lung Cancer
- (2009) Boone Goodgame et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Potent Phagocytic Activity with Impaired Antigen Presentation Identifying Lipopolysaccharide-Tolerant Human Monocytes: Demonstration in Isolated Monocytes from Cystic Fibrosis Patients
- (2009) Carlos del Fresno et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now